Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

bioAffinity Technologies (BIAF) Change in Accured Expenses (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Change in Accured Expenses for 4 consecutive years, with -$63487.0 as the latest value for Q3 2025.

  • On a quarterly basis, Change in Accured Expenses rose 2.09% to -$63487.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $80295.0, a 69.17% decrease, with the full-year FY2024 number at $248911.0, down 31.24% from a year prior.
  • Change in Accured Expenses was -$63487.0 for Q3 2025 at bioAffinity Technologies, up from -$322701.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $506025.0 in Q4 2023 to a low of -$322701.0 in Q2 2025.
  • A 4-year average of $17538.9 and a median of -$27987.0 in 2025 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: soared 645.7% in 2023, then tumbled 476.22% in 2025.
  • bioAffinity Technologies' Change in Accured Expenses stood at $67859.0 in 2022, then skyrocketed by 645.7% to $506025.0 in 2023, then dropped by 2.28% to $494470.0 in 2024, then tumbled by 112.84% to -$63487.0 in 2025.
  • Per Business Quant, the three most recent readings for BIAF's Change in Accured Expenses are -$63487.0 (Q3 2025), -$322701.0 (Q2 2025), and -$27987.0 (Q1 2025).